Fred Hite Sells 6,443 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite sold 6,443 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the sale, the chief financial officer now owns 207,989 shares of the company’s stock, valued at approximately $5,170,606.54. This represents a 3.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

OrthoPediatrics Price Performance

KIDS stock opened at $25.15 on Thursday. The business’s 50-day moving average is $24.79 and its two-hundred day moving average is $25.53. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The firm has a market capitalization of $610.82 million, a P/E ratio of -20.45 and a beta of 1.22. OrthoPediatrics Corp. has a 1 year low of $21.02 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The firm had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. During the same quarter last year, the company earned ($0.23) earnings per share. Analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Stifel Nicolaus dropped their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, March 5th. Finally, Truist Financial dropped their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th.

Institutional Investors Weigh In On OrthoPediatrics

Several institutional investors have recently modified their holdings of KIDS. Mutual of America Capital Management LLC raised its stake in OrthoPediatrics by 195.1% in the third quarter. Mutual of America Capital Management LLC now owns 107,609 shares of the company’s stock valued at $2,917,000 after buying an additional 71,146 shares in the last quarter. Quest Partners LLC increased its holdings in shares of OrthoPediatrics by 924.4% in the 3rd quarter. Quest Partners LLC now owns 11,986 shares of the company’s stock valued at $325,000 after acquiring an additional 10,816 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of OrthoPediatrics during the 3rd quarter worth about $295,000. Charles Schwab Investment Management Inc. lifted its stake in OrthoPediatrics by 2.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 132,434 shares of the company’s stock worth $3,590,000 after purchasing an additional 2,661 shares during the last quarter. Finally, Quantbot Technologies LP boosted its holdings in OrthoPediatrics by 42.2% in the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after purchasing an additional 1,712 shares in the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.